Vol.74 No.6 November 2026
Disproportionality analysis of hypokalemia associated with tazobactam/piperacillin using the Japanese Adverse Drug Event Report database: evaluation of time-to-onset and patient demographics
1)Department of Pharmacy, Toyooka Public Hospital, 1094 Tobera, Toyooka, Hyogo, Japan
Abstract
Although hypokalemia induced by the penicillin-class antimicrobial agent tazobactam/piperacillin (TAZ/PIPC) is recognized as a severe adverse event, comprehensive evaluations using large-scale data remain limited. This study evaluated the association between TAZ/PIPC treatment and the risk of hypokalemia, the time-to-onset, and differences in reporting disproportionality based on the patient demographics using a spontaneous reporting database. A disproportionality analysis was conducted using data in the Japanese Adverse Drug Event Report database recorded from April 2004 to May 2025. The reporting odds ratio was calculated and compared with the values for benzylpenicillin, ampicillin, sulbactam/ampicillin, piperacillin, fosfomycin, meropenem, cefepime, and tazobactam/ceftolozane. Furthermore, the time-to-onset of hypokalemia was analyzed, and the degree of reporting disproportionality among patient demographic groups was compared using the relative reporting odds ratio (rROR).
Among 1,457,231 reports in the database, 5,470 cases of hypokalemia were identified, with TAZ/PIPC identified as the suspected drug in 43 cases. Among the compared antimicrobial agents, a safety signal was detected exclusively for TAZ/PIPC. The median time-to-onset was four days after initiation of treatment with TAZ/PIPC, with the majority of cases occurring within one week of treatment initiation. In the subgroup comparison using rROR, a significantly pronounced disproportionality was observed in females as compared with males (rROR 2.15, 95% confidence interval: 1.16-4.00). Conversely, no significant differences were confirmed based on older age (≥70 years) or estimated body mass index. TAZ/PIPC-associated hypokalemia tends to occur in the early stages of administration, with a particularly prominent disproportionality demonstrated in females. These findings suggest that this adverse event is likely due to the drug-specific pharmacological mechanisms rather than simple sodium loading or confounding by the treatment indication. Intensive electrolyte monitoring is recommended during the first week of TAZ/PIPC administration.
Key word
tazobactam/piperacillin, hypokalemia, antimicrobial stewardship
Received
March 6, 2026
Accepted
July 27, 2026
Jpn. J. Chemother. 74 (6): 753-761, 2026


